Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:710370.
doi: 10.1155/2014/710370. Epub 2014 Aug 20.

Subjects with impaired fasting glucose: evolution in a period of 6 years

E Leiva  1 , V Mujica  2 , R Orrego  1 , S Wehinger  1 , A Soto  3 , G Icaza  3 , M Vásquez  1 , L Díaz  1 , M Andrews  4 , M Arredondo  4
Affiliations

Subjects with impaired fasting glucose: evolution in a period of 6 years

E Leiva et al. J Diabetes Res. 2014.

Abstract

Aim: To study the evolution of impaired fasting glucose (IFG), considering glucose and HbA1c levels and risk factors associated, in a period of 6 years.

Methods: We studied 94 subjects with impaired fasting glucose (IFG) that were diagnosed in 2005 and followed up to 2012. Glucose and HbA1c levels were determined. A descriptive analysis of contingence charts was performed in order to study the evolution in the development of type-2 diabetes mellitus (T2DM).

Results: Twenty-eight of ninety-four subjects became T2DM; 51/94 remained with IFG; and 20/94 presented normal fasting glucose. From the 28 diabetic subjects, 9 had already developed diabetes and were under treatment with oral hypoglycemic agents; 5 were diagnosed with plasma glucose < 126 mg/dL, but with HbA1c over 6.5%. In those who developed diabetes, 15/28 had a family history of T2DM in first relative degree. Also, diabetic subjects had a BMI significantly higher than nodiabetics (t test: P < 0.01). The individuals that in 2005 had the highest BMI are those who currently have diabetes.

Conclusion: The IFG constitutes a condition of high risk of developing T2DM in a few years, especially over 110 mg/dL and in obesity patients.

PubMed Disclaimer

References

    1. Ministerio de Salud. Encuesta Nacional de Salud ENS Chile 2009-2010. http://web.minsal.cl/portal/url/item/bcb03d7bc28b64dfe040010165012d23.pdf.
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. 2002;346(6):393–403. - PMC - PubMed
    1. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet. 2006;368(9541):1096–1105. - PubMed
    1. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753–759. - PubMed
    1. Valdés S, Rojo-Martínez G, Soriguer F. Evolution of prevalence of type 2 diabetes in adult Spanish population. Medicina Clinica. 2007;129(9):352–355. - PubMed

MeSH terms